Drugs for Neglected Diseases initiative
Recent meetings
| Date | Commissioner / Cabinet | Topic | File |
|---|---|---|---|
| 01 Apr 2025 | Felice Zaccheo Head of Unit | Plenary Feedback round on previously held GGIA Working Group sessions of 9 different thematical groups regarding Latin America and the Caribbean (LAC). | — |
| 01 Apr 2025 | Felix Fernandez-Shaw Director | Plenary Feedback round on previously held GGIA Working Group sessions of 9 different thematical groups regarding Latin America and the Caribbean (LAC). | — |
| 01 Apr 2025 | Felice Zaccheo Head of Unit | Plenary Feedback round on previously held GGIA Working Group sessions of 9 different thematical groups regarding Latin America and the Caribbean (LAC). | SRC |
| 01 Apr 2025 | Felix Fernandez-Shaw Director | Plenary Feedback round on previously held GGIA Working Group sessions of 9 different thematical groups regarding Latin America and the Caribbean (LAC). | SRC |
| 28 Nov 2024 | Laurent Muschel Acting Director-General | Development of MCM against climate related health threats | SRC |
| 28 Nov 2024 | Laurent Muschel Acting Director-General | Development of MCM against climate related health threats | — |
| 22 Apr 2024 | Iliana Ivanova Commissioner | Support of the European Framework Programme for health research and innovation | SRC |
| 22 Apr 2024 | Iliana Ivanova Commissioner | Support of the European Framework Programme for health research and innovation | — |
| 01 Jul 2022 | Sandra Gallina Director-General | Conversation with DNDi and GARDP on possible collaboration for DG Santé | — |
| 01 Jul 2022 | Sandra Gallina Director-General | Conversation with DNDi and GARDP on possible collaboration for DG Santé | SRC |
| 14 Jan 2022 | Jean-Eric Paquet Director-General | HERA | — |
| 14 Jan 2022 | Jean-Eric Paquet Director-General | HERA | SRC |
Mission & Goals
Founded in 2003 to address the needs of patients with the most neglected diseases, DNDi is a collaborative, patients’ needs-driven, not-for-profit drug R&D organization. The vision of the organization is to improve the quality of life and the health of people suffering from neglected diseases by using an alternative model to develop drugs for these diseases and by ensuring equitable access to new and field-relevant health tools. In this not-for-profit model, driven by the public sector, a variety of players collaborate to raise awareness of the need to research and develop drugs for those neglected diseases that fall outside the scope of market-driven R&D. They also build public responsibility and leadership in addressing the needs of these patients.
EU Legislative Interests
Advocacy of global policy related to neglected diseases; political leadership, sustainable financing, and sound public policies for R&D in neglected diseases; treatment development for neglected diseases; strengthening of research capacities in low- and middle-income countries. Following and contributing to policies and public consultations involved in shaping EDCTP3, Horizon Europe (FP10), MAV+, and Product Development Partnership (PDP) forum and EU research funding policies. Focus on EU commission and other key institutions to gather political support to develop a sustainable global framework for innovations of public health importance
Communication Activities
Participation at EU conferences, Research and Innovation forums, EDCTP forums. Communications activities in close collaboration with EDCTP projects running at DNDi and their partners.
Interests Represented
Does not represent commercial interests
Member Of
Swiss Alliance against Neglected Tropical Diseases (SANTD) https://santd.ch/ German NTD network https://dntds.de/members-observers.html Global health Hub https://www.globalhealthhub.de/de/ueber-den-hub/mitglieder WIPO https://www.wipo.int/members/en/organizations.jsp?type=NGO_INT
Organisation Members
http://www.dndi.org/about-dndi/dndi-worldwide/ http://www.dndi.org/about-dndi/our-people/
Connected Legislation